AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02521909 — intervention group
Intervention type: DEVICE
Intervention: Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
Study NCT02521909 — intervention group
Intervention type: DEVICE
Intervention: NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
Study NCT01927393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive PCPI
Study NCT01927393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive education sessions
Study NCT03037125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split Crest with PRF
Description: Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
Study NCT03037125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split Crest without PRF
Description: Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
Study NCT01927393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01927393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01927393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01927393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01969448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Study NCT03375294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
Study NCT02182869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent® HFA inhalation aerosol
Study NCT02182869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent® CFC inhalation aerosol
Study NCT01927393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone-based intervention
Description: Receive telephone contacts
Study NCT03945734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
Study NCT00129792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary supplement for weight loss
Description: The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
Study NCT00129792 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dietary supplement for weight loss
Description: The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
Study NCT00129792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.
Study NCT00129792 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.
Study NCT00129792 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education and counseling for weight loss
Description: Hour and a half weight loss education session weekly for 12 weeks.
Study NCT01250483 — intervention group
Intervention type: OTHER
Intervention: PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography
Study NCT03793686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBCLN-003
Description: Investigational drug
Study NCT03793686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03060967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities of food and control images
Study NCT02965066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: Newly developed intermittent catheter
Study NCT05818618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Topical Gel
Description: Topic Clobetasol gel applied locally on OLP lesions.
Study NCT05818618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral gel applied locally on OLP lesions.
Study NCT02043613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextually enhanced physical surroundings of exercise
Description: Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study.
Study NCT02043613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Description: The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
Study NCT02965066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Speedicath
Description: Marketed Coloplast Speedicath catheter
Study NCT03288740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Study NCT03288740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide 0.5 mg)
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Study NCT03288740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Description: A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Study NCT03288740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide 1.0 mg)
Description: A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
Study NCT01861145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bed Alarm
Description: The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
Study NCT01861145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed Alarm
Description: The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
Study NCT01861145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasonex
Description: Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
Study NCT04376099 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oxygen pressure measurement during the treadmill test
Description: Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg.
Study NCT02383498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care
Study NCT02383498 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard of care
Study NCT02664207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Fetal Repair of Myelomeningocele
Description: Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
Study NCT02565732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A, Dose A, Topical
Study NCT02565732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A, Dose B, Topical
Study NCT02565732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo, Dose C, Topical
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo as nasal spray.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agomelatine
Description: Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Prolonged Release
Description: Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
Study NCT03852160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone Prolonged Release
Description: Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
Study NCT05461183 — intervention group
Intervention type: OTHER
Intervention: Retrospective database analysis
Description: This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
Study NCT02383498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3X-BT Actigraph
Description: wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
Study NCT02383498 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wGT3X-BT Actigraph
Description: wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
Study NCT02043613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular exercise
Description: The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
Study NCT00118131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00118131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00283491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Lactobacillus plantarum 299v
Description: 10\^11 cfu/meal in 2 meals on 2 consecutive days
Study NCT00283491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Lactobacillus plantarum 299v
Description: Inactive form of the active treatment but with the fermentation products in the same concentration
Study NCT02680431 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 10 mL venous blood sample for analysis of plasma
Study NCT01908413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-427
Description: CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
Study NCT06305130 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00476632 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 50 Minute Interview
Study NCT02245061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paired pulses cortical electrical stimulation
Study NCT00687310 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational intervention
Description: Tailored asthma education based on needs assessment
Study NCT01362127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
Study NCT01362127 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
Study NCT01962181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Description: Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
Study NCT01962181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04461366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency
Description: The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
Study NCT04461366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
Study NCT01007565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periarticular anesthetics injection
Description: Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
Study NCT01822574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting Guide Technique
Description: The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.